Europe — EMA
Kivizidiale (Timolol, Travoprost)
GNH USA supplies Kivizidiale (Timolol/Travoprost), a beta‑blocker and prostaglandin analog combination for primary open‑angle glaucoma and ocular
Request sourcing
What is Timolol, Travoprost?
Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and prostaglandin analog combination presented as eye drops for ocular use. It treats primary open‑angle glaucoma and ocular hypertension in adults.
GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Timolol, Travoprost used for?
Kivizidiale is indicated for conditions involving elevated intra‑ocular pressure.
Primary open‑angle glaucoma: lowers intra‑ocular pressure to reduce the risk of optic nerve damage. Ocular hypertension: reduces intra‑ocular pressure to prevent progression to glaucoma.
What are the side effects of Timolol, Travoprost?
Kivizidiale may cause ocular and systemic adverse reactions.
Common Side Effects: - Eye irritation or burning sensation - Blurred vision after instillation - Redness of the conjunctiva - Dry eye or itching
Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Significant worsening of glaucoma - Systemic bradycardia or hypotension - Bronchospasm in susceptible individuals
What precautions apply to Timolol, Travoprost?
Before using Kivizidiale, consider the following safety measures.
Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. Evaluate respiratory condition: use with caution in asthma or COPD. Monitor intra‑ocular pressure: ensure adequate pressure reduction after initiation. Avoid concurrent use with other beta‑blocker eye drops. Store at room temperature: keep in the original container, protect from light and moisture.
What does Timolol, Travoprost interact with?
Kivizidiale can interact with other medications; review patient medication lists.
Major Interactions (Avoid): - Systemic beta‑blockers (e.g., propranolol): may cause additive bradycardia. - Non‑selective beta‑blocker inhalers: increase risk of bronchospasm. - Other prostaglandin analog eye drops: may exacerbate ocular side effects.
Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitor eye drops (e.g., dorzolamide): may produce excessive IOP lowering. - Topical corticosteroids: can diminish the IOP‑lowering effect. - Antihistamine eye drops: may increase ocular irritation.
